Media reports claiming failure in procuring contraceptives are Ill-informed, misleading

Responding to some media reports alleging that India’s family planning program is likely to get severely affected due to failure in procuring contraceptives by the country’s central procurement agency, the Central Medical Services Society (CMSS) under the government of India has issued a response stating that such reports are ill-informed and provides misleading information.

The Central Medical Services Society (CMSS), New Delhi, an autonomous body and a Central Procurement Agency under Union Ministry of Health and Family Welfare procures condoms for National Family Planning Programme and National AIDS Control Programme.

For more details, check out the link given below:

We Have Enough Contraceptives In India: Govt Debunks Myths On Condom Shortage

Powered by WPeMatico

Health Bulletin 14/December/2023

Here are the top health stories for the day:

Govt junks media reports claiming contraceptive shortage in India 

Responding to some media reports alleging that India’s family planning program is likely to get severely affected due to failure in procuring contraceptives by the country’s central procurement agency, the Central Medical Services Society (CMSS) under the government of India has issued a response stating that such reports are ill-informed and provides misleading information.

The Central Medical Services Society (CMSS), New Delhi, an autonomous body and a Central Procurement Agency under Union Ministry of Health and Family Welfare procures condoms for National Family Planning Programme and National AIDS Control Programme.

For more details, check out the link given below:

We Have Enough Contraceptives In India: Govt Debunks Myths On Condom Shortage


Either complete registration process or get your PG, SS admission cancelled: NBE tells 326 Diploma, DNB, FNB doctors

Noting that around 326 doctors have not completed their registration formalities with the National Board of Examinations (NBE) for the year 2021 and 2022, the NBE has now given them a last warning to either complete the process by December 15th or get their admissions cancelled.

Through a recent notice, National Board of Examinations (NBE) has informed regarding the Cancellation of candidature of 2021 and 2022 Admission Session trainees to pursue NBEMS courses.

For more details, check out the link given below:

Either Complete Registration Process Or Get Your PG, SS Admission Cancelled: NBE Tells 326 Diploma, DNB, FNB Doctors

How much money is being spent on doctor in conferences? Pharma companies, associations may soon have make those declarations

The pharma companies and medical associations might need to disclose in the future the money they spend per doctor in conferences, a recent media report by The Print has stated.

Recommendations in this regard were made by a high-level government panel set up to review the Uniform Code of Pharmaceutical Marketing Practices (UCPMP).

Apart from this, the panel has also suggested that the doctors cannot be given brand reminders, in case the value exceeds Rs 1,000 per item. Brand reminders refer to products that are offered for free to doctors by marketing representatives of pharma companies with the names of popular medicinal brands.

For more details, check out the link given below:

How Much Money Is Being Spent On Doctor In Conferences? Pharma Companies, Associations May Soon Have Make Those Declarations

Powered by WPeMatico

Study reveals Hashimoto’s thyroiditis does not increase melanoma risk

USA: A retrospective matched cohort study found that Hashimoto’s thyroiditis does not raise the risk of melanoma and nonmelanoma skin cancer (NMSC).

The findings published in the Archives of Dermatological Research suggest that the local proinflammatory environment present in Hashimoto does not significantly contribute to the risk of melanoma.

Hashimoto’s is an autoimmune disorder. Normally, the autoimmune system protects the body by attacking viruses and bacteria. But with the disease, the immune system attacks the thyroid gland by mistake. The thyroid fails to produce sufficient thyroid hormone, resulting in body dysfunction.

An inflammatory microenvironment has been suggested to raise the risk of malignant melanoma, indicating that melanoma may be related to an inflammatory state. Hashimoto’s thyroiditis is one of the most common autoimmune diseases, yet no study has been conducted on its relationship with melanoma.

B. G. Gorman, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA, and colleagues aimed to determine whether Hashimoto’s increases the risk of developing melanoma in a retrospective study.

For this purpose, the researchers identified a retrospective, validated cohort of patients with Hashimoto’s diagnosis between 2005 and 2020 using the Olmsted County database. Patients were sex and age-matched to controls without a Hashimoto diagnosis. The study’s primary outcomes were the melanoma development and the time to first diagnosis of melanoma.

The study led to the following findings:

  • 4805 patients were included in the study, with 36% having a diagnosis of Hashimoto’s.
  • Hashimoto’s patients had no significant difference in risk of melanoma (relative risk 0.96) or nonmelanoma skin cancer (relative risk 0.95) compared with matched controls, suggesting that, despite its potential pro-inflammatory effects, Hashimoto’s thyroiditis does not appear to contribute to the risk of melanoma significantly.

“The study findings suggest that Hashimoto’s thyroiditis does not increase the risk of melanoma and NMSC,” the researchers wrote.

“There may be a need for larger studies to characterize the relationship between these diseases further,” they concluded.

Reference:

Gorman, B.G., Campbell, E., Mullen, B.L. et al. Association between Hashimoto’s thyroiditis and melanoma: a retrospective matched cohort study. Arch Dermatol Res 315, 2721–2724 (2023). https://doi.org/10.1007/s00403-023-02669-4

Powered by WPeMatico

71 seats available for INI SS January 2024 at JIPMER: Know eligibility criteria, seat matrix, fee, all admission details here

Puducherry: Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) has released the information brochure regarding the admission procedure for the INI SS ( DM/MCh) course – January 2024 session concerning the first counselling for students.

As per the notice, the allotted candidates need to report by 18th December 2023 from 9:30 AM to 11:30 AM at the Academic Section, Third floor, JIPMER Academic Centre (JAC). Except 17th December 2023, i.e., Sunday.

For candidates who choose Option 1 in the first counselling (accepted the seat): The admission process will span over a minimum of two working days.

Tasks to be completed before reaching the admission venue –

Complete the Health-Care Professional ID Registration –

Steps for registration in NDHM / ABDM (Health-Care Professional ID Registration –

1. Click the below mentioned link to Register ‘Professional Healthcare ID’. The link is mentioned in the notice below.

2. Click on ‘Create Your Healthcare Professional ID now’. Step 3: Click on ‘I am Healthcare Professional’.

3. Click on ‘Generate via Aadhaar’. Step 5: Enter your Aadhaar Number.

4. Click on ‘I agree’ and click on ‘Submit’.

5. The candidates will get a 6-digit ‘OTP’ to their Aadhaar Registered Mobile Number. Step 8: Enter the OTP and Click ‘Login’.

6. After logging in, enter your Mobile Number.

7. The candidates will get again 6 digit ‘OTP’ on their mobile number. Step 11: Enter OTP and click on Login.

8. After logging in, create your ‘User Name’ & ‘Password’ (Password must be 8 characters, Upper case, lower case, Alphanumeric and special character).

9. Select ‘I am Healthcare Professional’. Step 14: Select ‘Modern Medicine’.

10. Enter your email address and click on ‘submit’.

11. After Submitting, the candidates will get OTP on their email for verification; after verification, their Registration will be completed, and you will receive a 14-digit Professional Healthcare ID number, take a printout of this page and submit the same at the time of document verification.

Fill out the E-form by clicking the link mentioned in the notice below & take a printout after final submission.

Forms to be printed and brought to the venue –

1. E-Form as mentioned above

2. ID card form – all the fields should be filled and in block letters (Annexure 1)

3. Joining letter and joining report formats (Annexures 2 & 3)

4. Hostel application form (if applicable) (Annexure 4)

5. Photocopy of Aadhaar card and PAN card (original should be brought during admission for verification)

On the day of reporting –

The following steps should be completed in the given order –

Day 1 –

Please provide an Institute Allocation Slip (printed after choosing Option-I or Option-II in the AIIMS portal) and print the e-form given above to the team and take a seat.

The candidates will be called at certificate verification desks inside the hall. Please produce all required documents in original, 1 set of photocopies of the original certificates, and 4 passport-size photographs.

After successful certificate verification, you will be given a form for Medical Examination by the team. The place of Medical Examination will be informed on the day of reporting. The duly signed Medical Examination report should be submitted back to the admission team. MEDICAL EXAMINATION WILL NOT BE CONDUCTED ON SATURDAYS.

Day 2 –

Submission of agreement form: A soft copy of the Resident Agreement form will be provided to the candidates; they have to go out and get it printed on Stamp Paper, and they have to fill it out as per the instructions given by JIPMER authorities at the time of document verification and submit to the authorities after filling it.

Complete the fee payment procedure through the SBI Collect payment portal for JIPMER at the link mentioned in the notice below.

Search for “JIPMER” in the search bar (Search by Institution / Organisation Name), and Select JIPMER PONDICHERRY from the two search results. Clicking on “JIPMER PONDICHERRY will redirect you to the next web page.

Choose the “Academic fee – MCh DM MD MS PDF PDCC” option in the dropdown menu given against the Payment Category. Refer to the prospectus for the correct split-up of fees (as given on page number 7 of Prospectus Part B for JIPMER).

The fee, once paid, cannot be refunded under any circumstances. Submit the hard copy of the fee payment receipt to the admission team.

The following will be issued to the candidates after completion of the above steps –

1. Bonafide certificate (certifying that the original documents are retained by the institute)

2. Provisional Admission order

Submit –

1. Hostel application form (if needed).

2. ID card form. The form has a field for the residential address (in Puducherry). The candidates may fill the field either after allotment of a hostel room or after renting accommodation outside the campus and submit this form.

The filled-in joining letter and joining report forms should be submitted to the respective department office on July 1, 2022. The joining report will be sent to the Academic Section by the department later through the proper channel.

If any candidate who has been allotted a seat in JIPMER chooses OPTION-1 and reports for admission in JIPMER as per the schedule given in the INI-SS result notification, his / her certificates will be retained after verification of the same. If any such candidate decides to leave the seat after submission of certificates to JIPMER authorities but before completion of joining / admission formalities and getting admission order / joining the department, he / she will be liable to pay the penalty to JIPMER which is Rs. 3 Lakhs. Additionally, the fee paid by him/her for admission will not be refunded.

Subject to the result of facial and iris verification.

For candidates who choose Option 2 –

Candidates should report as per the schedule mentioned above and submit either of the certificates mentioned in the prospectus.

Or

Security deposit as mentioned in the INI-SS result notification.

A Bonafide certificate will be issued for the retained certificates.

Seats vacant –

A total of 71 seats are vacant. DM Courses have 39 seats, and MCH courses have 32 seats vacant. The detailed course-wise seat matrix is enclosed in the notice below. The number and distribution of seats are subject to variation based on any periodic directives from the Competent Authority.

Eligibility criteria –

1. Candidates should be Indian Nationals.

2. Candidates should have passed MD/MS/DNB degrees from any Institute/University recognized by the National Medical Commission (NMC).

3. The degree mentioned above must be registered with the National Medical Commission/State Medical Council.

4. Candidates should have completed the qualifying postgraduate course on or before January 31, 2024.

DM courses

Eligibility

Critical Care

MD/DNB Anaesthesiology/General Medicine/Pulmonary Medicine

Cardiac Anaesthesia

MD/DNB Anaesthesiology

Neuro Anaesthesia

Cardiology

MD/DNB General Medicine/Paediatrics/Pulmonary Medicine

Clinical Pharmacology

MD/DNB General Medicine/Pharmacology/Paediatrics

Clinical Immunology & Rheumatology

MD/DNB Degree in General Medicine/Paediatrics

Endocrinology

Nephrology

Neurology

Medical Oncology

MD/DNB Medicine/Paediatrics/Radiotherapy

Neonatology

MD/DNB Paediatrics

Paediatric Critical care

Medical Gastroenterology

MD/DNB General Medicine/Paediatrics

Neuroimaging and Interventions

MD/DNB Radiodiagnosis

MCh courses

Eligibility

Urology

MS/DNB General Surgery

CTVS

Neurosurgery

Surgical Gastroenterology

Plastic Surgery

Paediatric Surgery

Surgical Oncology

MS/DNB General Surgery/Obstetrics & Gynaecology/ Otorhinolaryngology
(ENT)/Orthopaedic Surgery

Gynecological Oncology

MD/MS/DNB Obstetrics & Gynaecology

Sponsored category (Government – State/Central Services) –

A candidate applying under a sponsored category is required
to fulfill the following conditions duly certified by his/her
sponsoring/deputing authority/employer. The candidate is required to submit the
scanned copy of the sponsorship certificate in the format as given in the
Prospectus Part- A.

In case the applicant is not able to upload the sponsorship
certificate at the time of submission of the online application, he/she is
permitted to upload a scanned copy of the sponsorship certificate (.jpg/pdf) using
his/her login credentials as mentioned in the Prospectus Part- A in the
database. Non-receipt of scanned copy in the database of such candidate will
lead to automatic rejection of his/her application, and a hall ticket will not be
generated/issued. The sponsored certificate should contain the following
declaration by the sponsoring authority.

1. That the candidate concerned is a permanent or regular employee of the deputing/ sponsoring authority and should have been working for at least the last three years (as of 31st December 2023 for the January 2024 session)

2. After getting training at JIPMER, Puducherry, the candidate will be suitably employed by the deputing/sponsoring authority to work for at least five years in the specialty in which training is received by the candidate at JIPMER.

3. No financial implications, in the form of emoluments/stipend, etc., will devolve upon JIPMER, Puducherry, during the entire period of his/her course and such payment shall be the responsibility of the sponsoring authority.

Deputation/Sponsorship of candidates holding tenure appointments (like house job, Junior or Senior Residency, ad-hoc or contract, or honorary appointment against a leave vacancy) shall NOT be accepted. Deputation/Sponsorship of any candidate by private hospitals, institutes, or nursing homes is not accepted. The sponsoring Institute should not nominate more than one candidate for each of the specialties specified in the distribution of seats in the discipline.

Sponsorship/Deputation of candidates will be accepted only from the following –

1. Central or State Government Departments/Institutions

2. Autonomous Bodies of the Central or State Governments

3. Public sector colleges affiliated to Universities and recognized by the National Medical Commission. For candidates deputed/ sponsored by the Medical College affiliated with Universities and recognized by the National Medical Commission, a deputation/sponsorship certificate signed by the Principal of the Medical College concerned ONLY shall be accepted.

Selection of Sponsored Candidates –

Sponsored/Deputed candidates are also required to appear in the common entrance examination. Separate merit lists will be drawn for each of the specified disciplines for sponsored candidates. If selected for admission to any course of JIPMER, these candidates are required to make their own arrangements for stay during the period of their course. The sponsored candidates selected for admission will be granted only one-month time to produce Sponsorship/Relieving/Study leave/NOC certificates from the date of announcement of the results of the respective counselling. No further extension will be allowed under any circumstances. Vacant seats under the sponsored category will not be transferred to the general category.

Method of selection and admission process –

The selection of candidates is based on the INI-SS entrance examination without an interview component. Allotment of the institution is based on merit scores and the choice exercised by the candidates in the online INI-SS counseling process conducted by AIIMS, New Delhi.

Candidates who have opted for a seat at JIPMER and were selected through counseling shall undergo a medical examination and biometric (iris/signature) verification. After due verification of the documents, clearance of biometric parameters, and medical fitness certified by a competent authority nominated by the Institute, an admission letter will be issued. The Original Certificates will be retained in the Academic Section and returned only after the candidate completes the course or if relieved before completion of the course for any reason. The academic session will commence on January 01, 2024.

It is mandatory for all candidates to be physically present in person for admission. No request for an authorized representative on behalf of the candidate will be entertained. If a candidate fails to come for admission in person, he/she will be marked as absent, and the admission will be canceled. Admissions close on February 29, 2024.

Verification of original certificates –

FULL NAME entered by the candidate must match with both his/her Govt. Photo ID Card (Aadhar Card / PAN card / Identity Card / Driver’s License etc.) and MD/MS/DNB Degree Certificate. (Spelling and order must be same – if it is not the same, the candidate is advised to get it changed in the above-mentioned document/documents.

The candidate should submit the following certificates in original along with one set of self-attested copies at the time of admission – 

1. Hall Ticket for INISS entrance examination.

2. Rank Letter and Seat Allotment letter.

3. Proof of Date of Birth (Birth Certificate or X Std. Certificate).

4. MBBS Degree Certificate

5. MD/MS/DNB Degree Certificate/Provisional Pass Certificate.

6. MD/MS/DNB Marksheet

7. Character and Conduct Certificate from the Head of the Institute last studied.

8. Residence Certificate issued by Revenue Authority, not below the rank of Tahsildar

9. Transfer Certificate from the Head of the Institution last studied / Migration Certificate from the University last studied. *

10. Permanent Medical Registration Certificate from the National Medical Commission (or State Medical Council)

11. Registration of Additional Medical qualifications with the National Medical Commission

12. The service candidate should produce an NOC/Relieving Order and a certificate granting study leave with or without pay, as the case may be (If applicable)

13. Four Passport size color photographs identical to the photograph uploaded in the application.

A maximum one-week time may be granted from the date of issue of the provisional admission order to submit this certificate; failure to submit it will lead to cancellation of admission.

If the certificates are in a language other than English, an English translation attested by a Gazetted Officer should be produced.

A candidate will be eligible for admission if his /her Biometric fingerprint or iris scan, photo, and necessary certificates are found in order. If there is any mismatch, the seat allotment will be canceled, apart from proceeding with legal action deemed fit by the Institution, and no further correspondence will be entertained in this regard. If a candidate is already pursuing any other courses at any Institution, he/she shall submit the necessary no-objection certificate from the concerned Institution authority at the time of admission. It will be applicable to JIPMER candidates also.

Candidates must join the course after the medical examination on or before the stipulated date given in the letter of admission. The admission of candidates who fail to pay the specified fee or fail to report for duty to the concerned Head of the Department will be treated as canceled. No further correspondence will be made in this regard. Extension of joining time shall not be granted under any circumstances. The Senior Resident should send his/her joining Report to the Director through the concerned Head of the Department.

If a Senior Resident remains continuously absent or unauthorized for more than 30 days after joining, the admission will be canceled, and the necessary penalty will be levied. Admission to the course will be provisional, subject to the recognition of the qualifying examination of individual candidates by JIPMER. Admission fees paid will not be refunded.

Fee structure – 

Sl.No.

Description

Fee in INR

1

Admission Fee

3,000

2

Tuition Fee (per annum)

2,200

3

Learning Resource Fee (per annum)

15,000

4

Corpus Fund on Academic Fee (per annum)

110

5

Student information details (per annum)

1,500

6

Identity Card Charges

150

7

Caution deposit (refundable *)

3,000

TOTAL

24,960

Caution deposit will be refunded only on successful
completion of the course. Fees, once paid, will NOT be refunded under any
circumstances.

Hostel charges –

Sl. No.

Description

Fee in INR

1.

Hostel Caution Deposit (refundable)

5,000

2.

Hostel Mess Deposit (refundable)

3,000

3.

Student Recreation/Amenities (per annum)

1,000

4.

Establishment Charges (per annum)

6,000

5.

Room Rent (per annum) including Electricity Charges for a single
room = Rs.9,000/-

9,000

TOTAL

24,000

To view the notices, click on the links below –

https://medicaldialogues.in/pdf_upload/iniss-prospectus-jan-2024-part-b-jipmer-227768.pdf

Powered by WPeMatico

Noida: Yatharth Super Specialty Hospital, Apex Eye and IVF Center slapped Rs 5 lakh fine each for illegal billboard ads

Noida: The Greater Noida Industrial Development Authority on Wednesday said it has slapped penalties worth Rs 5 lakh each on six entities, including two schools, a hospital, and a banquet hall, for illegally installing billboards for advertisements.

In total, penalties worth Rs 30 lakh were imposed on the offenders by the Urban Services Department which inspected different locations of the city on instructions of GNIDA’s Chief Executive Officer N G Ravi Kumar, it said in a statement.

Also Read:Nagpur Hospital fined Rs 50000 over biomedical waste violations

“The GNIDA’s team imposed fines on these illegal unipoles and directed the entities concerned to remove them immediately. The institutions that have been fined for illegal unipoles include Shri Ram Global School, Yatharth Super Specialty Hospital, Saawariya Banquet Hall, Delhi World Public School, Apex Eye and IVF Center, and Sumiram Sai Realtors,” the GNIDA said in the statement.

“A penalty of Rs 5 lakh each — Rs 30 lakh — has been imposed on these six institutions by the Urban Services Department of the authority. A warning has also been given to issue a recovery certificate if this amount of fine is not deposited in the authority’s account within a week,” it added.

Along with this, the illegal unipoles which do not have advertisements but disrupt traffic movement will also be removed, the local authority said.

GNIDA’s Officer on Special Duty Indu Prakash Singh said similar action against those setting up statutory poles illegally will continue in the future, according to the statement.

A unipole sign is a frame structure mounted atop a single column used in outdoor advertising.

Powered by WPeMatico

No shortage of TB drugs in India: Govt

New Delhi: The Ministry of Health & Family Welfare has informed that there is no shortage of anti-tuberculosis drugs in the country. There has been regular supply of Anti-TB drugs to all the State/UTs from the central level under the National TB Elimination Programme (NTEP) throughout the year and regular assessments are conducted to evaluate the stock positions at various levels, from central warehouses to peripheral health institutes.

Further, State/UTs have been provisioned with resources for local procurement for limited quantities as and when required to meet the emergent requirements.

The details of stock positions of anti-tuberculosis drugs placed are as under:

Stock of Anti TB Drugs as on 06-12-2023

Drug Name

Total Stock available

Stocks will last

(approx. months)

Tab. 2FDC (P) (H50 & R75)

18078984

More than 6 months

Tab.3FDC CP (A) (H75,R150 & E275)

159287016

For 4 months

Tab 3FDC(P) (H50, R75, Z150)

17889844

More than 6 months

Tab. 4FDC(A) (H75, R150, Z400 & E275)

94250072

For 4 months

Tab. Bedaquiline (BDQ)-L

9835849

More than 6 months

Cap. Clofazimine 100mg

7901607

More than 6 months

Cap. Clofazimine 50mg

129405

More than 6 months

Cap. Cycloserine 250mg

12591104

More than 6 months

Tab. Delamanid 50mg

3688946

More than 6 months

Tab. Ethambutol 100mg

40895959

More than 6 months

Tab. Ethambutol 800mg

2759910

For 3 months

Tab. Ethionamide 250mg

15096309

More than 6 months

Tab. Moxifloxacin 400mg

25720793

More than 6 months

Tab. Isoniazid 300mg

43951761

More than 6 months

Tab. Levofloxacin 250mg

10770158

More than 6 months

Tab. Levofloxacin 500mg

9862422

More than 6 months

Tab Linezolid 600mg

4190760

More than 6 months

Tab. Pyrazinamide 500mg

6262558

More than 6 months

Tab. Pyrazinamide 750mg

5862684

More than 6 months

Tab. Pyridoxine 100mg

20060750

More than 6 months

Read also: Vague and ill-informed: Centre dismisses claims on shortage of anti-TB drugs in India

Powered by WPeMatico

Acute Pulpitis: Dental Practice Perspective and Application of Aceclofenac Paracetamol Combination

Tooth pulp, a complex connective tissue within teeth, comprises nerves, blood vessels, and various cell types. Pulpitis is referred to as inflammation of tooth pulp, resulting from different irritant stimuli. Pulpitis can be categorized into focal reversible pulpitis, acute pulpitis, and chronic pulpitis.[1,2,3] Acute pulpitis is a painful dental condition characterized by inflammation in the tooth’s innermost pulp due to bacterial infections, often stemming

from tooth decay or trauma. It presents with a severe toothache, heightened sensitivity to temperature changes, localized swelling, and sometimes a bad taste in the mouth. [4]

Among Indian females, the lowest incidence of reversible pulpitis is in the 46-75 age group, while the highest is in the 18-30 age group. In contrast, the highest incidence of irreversible pulpitis is reported among males aged 18-30 years, with the lowest cases found in females aged 46-75 years. This brings out a unique pattern of acute pulpitis distribution in the Indian population.[5]

Effective pain management in acute pulpitis is essential for patient well-being and successful treatment outcomes. It alleviates discomfort during dental procedures, enhancing the overall treatment experience and ensuring patient comfort.[6]

Acute Pulpitis: Practice Perspective Overview

Etiology of Acute Pulpitis: Acute pulpitis results from bacterial invasion into the tooth’s pulp due to dental problems like cavities, trauma, or fractures, exacerbated by inadequate oral hygiene. Risk factors include environmental factors (lack of fluoridated water), medical conditions (diabetes), and habits (high-sugar diets, teeth grinding). Exposure to extreme temperatures, sugary foods, and chewing on hard objects can worsen inflammation and discomfort.[1]

Pathophysiology, Clinical Presentation & Evaluation of Acute Pulpitis: Dental pulp has A-delta and C-fiber nerve pathways that respond to rapid and slow pain stimuli. Pain thresholds differ by tooth region; factors like temperature changes or chemicals activate these nerves. Symptomatic reversible pulpitis causes short, sharp pain, usually triggered by cold, and it subsides when the cause is removed.[1,8]

Diagnosing acute pulpitis entails examining symptoms, signs of inflammation, and diagnostic tests. Pulp vitality, thermal sensitivity, and percussion evaluation help to assess the pulp’s condition. [9]

Differential diagnosis is crucial, considering conditions with similar symptoms such as apical periodontitis, marginal periodontitis, and non-dental conditions like herpes zoster infection, requiring careful evaluation for accurate diagnosis of acute pulpitis.[10,11,12]

Assessing pain in cases of acute pulpitis entails a comprehensive examination of pain intensity and its distinctive attributes as reported by the patient. The Visual Analogue Scale (VAS) is a widely employed method to gauge pain intensity, with patients rating their pain on a scale ranging from 0 to 10. In addition to VAS, alternative scales like verbal rating scales and behavioral rating scales can also be utilized to effectively evaluate and document the patient’s pain experience.[13]

Management Approaches in Acute Pulpitis

Managing acute pulpitis conservatively involves precise diagnosis through clinical assessment and diagnostic tests. Pain relief is a priority, optimally utilizing analgesics and anti-inflammatory medications and considering antibiotics for treating infections, as indicated. Local anesthesia provides immediate relief during pulp capping with materials like calcium hydroxide or Mineral Trioxide Aggregate (MTA). A pulpotomy retains tooth vitality for reversible pulpitis by partially removing the inflamed pulp. Patient education on oral hygiene and dietary modifications is crucial, along with regular follow-up & monitoring to preserve tooth function and health.[14,15]

Dentists are pivotal in acute pulpitis management, focusing on pain control, patient education, and informed consent. Their expertise in understanding pain mechanisms and diagnostics is essential for effective treatment. Dentists need a deep knowledge of applying drug mechanisms to address endodontic pain, ensuring patient comfort and well-being.[16] Nonsteroidal anti-inflammatory drugs (NSAIDs) find frequent application in the prevention and management of postoperative endodontic pain. In dentistry, a principle often referred to as the ‘3-D’s’ (comprising diagnosis, dental treatment, and drug therapy) serves as a guiding framework for pain management, where pharmacological interventions are considered supplementary to dental procedures.[17,18]

Pharmacological Management in Acute Pulpitis

Effective and safe pain management is a paramount objective in dental practice, particularly in the context of pulpitis and pulpitis-related pain. Dental procedures, especially those addressing acute pulpitis, can induce discomfort and postoperative pain. Hence, dentists must employ suitable analgesics to ensure both the treatment’s success and the alleviation of pain linked to inflammation and surgical interventions in pulpitis cases.[19] The pharmacological therapies can be broadly grouped as follows:

  • Pain Relief Medications: Non-steroidal anti-inflammatory drugs (NSAIDs) for pain and inflammation. Paracetamol for pain and associated pyrexia relief. [20]
  • Opioids: Opioids may be considered for severe pain management in acute pulpitis.[20]
  • Steroids: Steroids such as dexamethasone may be considered in cases of acute pulpitis with significant inflammation to help reduce swelling and discomfort.[20]
  • Multimodal drug therapy: It involves using a combination of medications with different mechanisms of action to manage pain and inflammation effectively. [21]

Clinical Applicability of Aceclofenac and Paracetamol Combination in Acute Pulpitis

Aceclofenac, an oral NSAID, effectively manages painful inflammatory conditions like pulpitis. It’s known for tolerability and fewer gastrointestinal side effects, leading to better patient compliance. NSAIDs, including Aceclofenac, play a crucial role in managing pulpal pain before and after dental procedures. [22]

Paracetamol is widely used as an analgesic and antipyretic. It works uniquely by targeting COX peroxidase activity, especially at low peroxide levels, focusing on the central nervous system without peripheral anti-inflammatory effects. Due to its effectiveness in managing pain, paracetamol is often combined with other NSAIDs and/or opioids to enhance overall pain relief.[19]

The synergistic combination of Aceclofenac and Paracetamol offers a well-rounded approach to dental pain management. While Aceclofenac tackles inflammation at the tissue site, Paracetamol provides effective pain relief, making this combination a valuable consideration option for addressing pulpitis and pulpitis-related dental pain.[19,22,23]

Aceclofenac & Paracetamol: Clinical Evidence

Beneficial Effects of Aceclofenac and Paracetamol in Acute Pulpitis- An Indian Experience:

In a prospective clinical trial conducted by Solete and Ramesh, 120 patients with symptomatic irreversible pulpitis were enrolled. After root canal shaping and cleaning, participants were randomly divided into four groups: placebo, piroxicam 20mg, and two groups involving paracetamol and aceclofenac sodium, one with 325 mg of paracetamol and the other with 650 mg of paracetamol. Pain scores were assessed at 6, 12, and 24 hours. Results demonstrated that the combination of aceclofenac and paracetamol, when compared to a placebo, significantly reduced pain severity (p < 0.01) at 6 hours and exhibited superior pain reduction (p < 0.05) at 12 and 24 hours after root canal procedures. This study highlights the effectiveness of aceclofenac and paracetamol in alleviating dental pain in cases of acute pulpitis.[24]

Effectiveness of Aceclofenac in Acute Irreversible Pulpitis:

In a randomized double-blind trial study conducted by Pavithra P. et al. involving 85 patients with acute irreversible pulpitis, the analgesic effectiveness of Aceclofenac and Ibuprofen was compared. Among the 50 eligible patients, Group A received 400mg of Ibuprofen, while Group B received 100mg of Aceclofenac. Pain intensity, assessed using the Visual Analog Scale (0-100), significantly decreased after drug administration. At 45 minutes, Group B (Aceclofenac) demonstrated a notably lower pain intensity of 9.16+1.57 (P<0.001) compared to Group A (Ibuprofen) with 40.36+4.241. The study concluded that Aceclofenac 100mg exhibited a superior analgesic effect in patients with irreversible pulpitis, highlighting its potential for effective postoperative pain management. [22]

NSAID plus Paracetamol for Postoperative Endodontic Pain related to Pulpitis:

In a systematic review and meta-analysis encompassing 27 studies involving 2,188 patients, Shirvani et al. discovered that non-narcotic analgesics, including NSAIDs and paracetamol, exhibited remarkable effectiveness in mitigating postoperative endodontic pain. The meta-regression analysis revealed that non-narcotic analgesics, including NSAIDs and paracetamol were significantly more effective than placebo in managing post-operative pain, resulting in standardized mean differences of -0.50 (95% CI= -0.70, -0.30), -0.76 (95% CI= -0.95, -0.56), -1.15 (95% CI= -1.52, -0.78), and -0.65 (95% CI= -1.05, -0.26) immediately after the procedure and at 6, 12, and 24 hours post-operative follow-ups, respectively (P < 0.001). These findings underscore the efficacy of NSAIDs and paracetamol in managing post-endodontic dental pain, directly pertinent to relieving pain and inflammation related to pulpitis. [25]

Clinical Benefits of Aceclofenac and Paracetamol

  • Effective Pain Management: Aceclofenac and Paracetamol effectively relieve pain, making them suitable for painful dental conditions. [19,22,23]
  • Reduced Inflammation: Aceclofenac has anti-inflammatory properties that can help reduce inflammation associated with acute pulpitis. [22,23]
  • Comprehensive Relief: When Aceclofenac and Paracetamol are combined, they provide comprehensive relief by simultaneously addressing pain and fever, offering a comprehensive approach to symptom management. [19,22,23]
  • Synergetic Efficacy: This combination offers synergistic efficacy, effectively managing pain and fever and improving overall symptom control. [19,22,23]
  • Rapid Onset of Action: These medications are known for their quick onset of action, ensuring patients experience pain relief in a relatively short time. [19,22,23]

Take Home Messages

  • Acute pulpitis is a distressing dental condition characterized by inflammation in the innermost part of the tooth’s pulp, resulting in excruciating toothache and heightened sensitivity to temperature variations. [1,2,3]
  • Acute pulpitis primarily arises from bacterial invasion into the dental pulp, often stemming from dental issues like cavities, trauma, or poor oral hygiene. Environmental factors, systemic conditions, and lifestyle choices can further contribute to the risk of pulpitis. [1]
  • A rational approach to managing acute pulpitis includes precise diagnosis, appropriate pain relief through analgesics and anti-inflammatory medications, and, antibiotics, when necessary. The choice of pharmacological pain relief agents is important for prompt and effective pain relief. [14,15,16,17,18]
  • The combination of Aceclofenac and Paracetamol has shown remarkable efficacy in reducing dental pain in multiple clinical trials, making it a valuable consideration in acute pulpitis management.[19,22,23,24,25]
  • Aceclofenac and Paracetamol offer effective pain management, reduce inflammation, and provide dual-action pain relief. The combination exhibits a rapid onset of action, ensuring prompt relief for patients suffering from acute pulpitis.[19,22,23,24,25]

The combination of Aceclofenac and Paracetamol offers a promising approach to manage acute pulpitis effectively, providing comprehensive pain relief and improving patient well-being. [19,20,21,22,23,24,25]

References:

1. Dr Syed Gufaran Ali1, Dr Sanjyot Mulay. Pulpitis: A review. IOSR Journal of Dental and Medical Sciences,2015;14(8):92-97 https://www.researchgate.net/publication/281228037_Pulpitis_A_review

2. Mahsa Dastpak 1, Jamileh Ghoddusi 2, Amir Hossein Jafarian 3, Majid Sarmad Association between Clinical Symptoms and Histological Features of Molars with Acute Pulpitis. Iranian Endodontic Journal 2023;18(2): 91-95 https://pubmed.ncbi.nlm.nih.gov/37152857/

3. Bahadur F.Alieva , Latafat A. Gardashovab. Selection of an optimal treatment method for acute pulpitis disease. Procedia Computer Science,2017;120:539–546 https://doi.org/10.1016/j.procs.2017.11.276

4. Valentina NICOLAICIUC. Dental Pulpitis and Elements Of Endodontic Therapy. The State University Of Medicine and Pharmacy, Medicina,2013;107:181-186 https://propedeutica.usmf.md/wp-content/blogs.dir/130/files/sites/130/2018/03/Dental-pulpitis.pdf

5. Govula Kiranmayi, Lavanya Anumala, Richard Kirubakaran. Estimation of the Prevalence of Pulpitis in the Tertiary Care Hospital in Nellore district- A cross-sectional study. IOSR Journal of Dental and Medical Sciences,2018;18(8):63-66 https://www.researchgate.net/publication/338229885_Estimation_of_the_Prevalence_of_Pulpitis_in_the_Tertiary_Care_Hospital_in_Nellore_district-A_cross_sectional_study#:~:text=Results%3A%20The%20total%20prevalence%20rate,age%20group%2018%2D30%20years.

6. Thompson, W., Howe, S., Pitkeathley, C., Coull, C., & Teoh, L. Outcomes to evaluate care for adults with acute dental pain and infection: a systematic narrative review. BMJ Open,2022;12(2):e057934. https://doi.org/10.1136/bmjopen-2021-057934

7. Yu, C., & Abbott, P. V. An overview of the dental pulp: its functions and responses to injury. Australian Dental Journal,2007;52(s1):s4-16. https://doi.org/10.1111/j.1834-7819.2007.tb00525.x

8. Bender, I. Pulpal pain diagnosis—A review. Journal of Endodontics,2000;26(3):175–179. https://doi.org/10.1097/00004770-200003000-00012

9. Adriano Piattelli, MD, DDS* Tonino Traini, DDS, PhD*. DIAGNOSIS AND MANAGING PULPITIS: REVERSIBLE OR IRREVERSIBLE? Practical procedures & aesthetic dentistry,2007;19(2). https://www.researchgate.net/publication/6236907_Diagnosis_and_managing_pulpitis_reversible_or_irreversible

10. Klausen, B., Helbo, M., & Dabelsteen, E. A differential diagnostic approach to the symptomatology of acute dental pain. Oral Surgery, Oral Medicine, and Oral Pathology,1985;59(3):297–301. https://doi.org/10.1016/0030-4220(85)90170-7

11. Lopes, M. A., de Souza Filho, F. J., Jorge Júnior, J., & de Almeida, O. P. Herpes zoster infection as a differential diagnosis of acute pulpitis. Journal of Endodontics,1998;24(2):143–144. https://doi.org/10.1016/s0099-2399(98)80095-2

12. Tonetto, M. R., de Andrade, M. F., Bandéca, M. C., Kuga, M. C., Keine, K. C., Pereira, K. F., Magro, M. G., Diniz, A. C. S., Galoza, M. O. G., & de Barros, Y. B. A. M. Differential Diagnosis and Treatment Proposal for Acute Endodontic Infection. The Journal of Contemporary Dental Practice,2015;16(12):977–983. https://doi.org/10.5005/jp-journals-10024-1791

13. Korsantiia, N. B., Davarashvili, X. T., Gogiashvili, L. E., Mamaladze, M. T., Tsagareli, Z. G., & Melikadze, E. B. Correlation between dental pulp demyelination degree and pain visual analogue scale scores data under acute and chronic pulpitis. Georgian Medical News,2013;218:62-7.https://pubmed.ncbi.nlm.nih.gov/23787510/

14. Akhmedov Muzaffarbek Ulugbek ugli1. CONSERVATIVE TREATMENT OF PULPITIS. EURASIAN JOURNAL OF ACADEMIC RESEARCH,2021;1(3);635-342. https://zenodo.org/record/5055700

15. Yong, D., & Cathro, P. Conservative pulp therapy in the management of reversible and irreversible pulpitis. Australian Dental Journal,2021;66(S1)S4-S14. https://doi.org/10.1111/adj.12841

16. Khan, A. A., & Diogenes, A. Pharmacological management of acute endodontic pain. Drugs,2021;81(14):1627–1643. https://doi.org/10.1007/s40265-021-01564-4

17. Manuela Favarin SANTINI, Ricardo Abreu da ROSA, Maria Beatriz Cardoso FERREIRA, Fernando Branco BARLETTA, Angela Longo do NASCIMENTO, Theodoro WEISSHEIMER, Carlos ESTRELA, Marcus Vincius Reis SÓ. Medications used for prevention and treatment of postoperative endodontic pain: a systematic review. European Endodontic Journal,2020;6(1):15-24. https://doi.org/10.14744/eej.2020.85856

18. Hargreaves, K., & Abbott, P. V. Drugs for pain management in dentistry. Australian Dental Journal,2005;50(s2):S14-22. https://doi.org/10.1111/j.1834-7819.2005.tb00378.x

19. Kim, S.-J., & Seo, J. T. Selection of analgesics for the management of acute and postoperative dental pain: a mini-review. Journal of Periodontal & Implant Science,2020;50(2):68-73 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192823/

20. Akhil Rajput1 , Umesh Kumar2 , Nikhil Sinha3 , Gulshan Kumar4 , Ruchi Vashisht5 , Krishan Gauba6 , Anup Kanase. Emergency Pain Management of Untreated Pulpitis during COVID-19 Lockdown by Telephonic Communication. World Journal of Dentistry, 2022;13(4):358–361. https://doi.org/10.5005/jp-journals-10015-2067

21. Christina M. A. P. Schuh1†, Bruna Benso2,3† and Sebastian Aguayo2*. Potential Novel Strategies for the Treatment of Dental Pulp-Derived Pain: Pharmacological Approaches and Beyond. Frontiers in Pharmacology,2019;10. https://doi.org/10.3389/fphar.2019.01068

22. P.Pavithra, 2M. Dhanraj, 3 Prathap Sekhar. Analgesic Effectiveness of Ibuprofen and Aceclofenac in the Management of Acute Pulpitis – A Randomized Double-Blind Trial. International Journal of Pharmaceutical Sciences Review and Research,2015;35(2):70-74. https://globalresearchonline.net/journalcontents/v35-2/14.pdf

23. Joseph V. Pergolizzia , Peter Magnussonb,c, Jo Ann LeQuanga , Christopher Gharibod and Giustino Varrassie,f. The pharmacological management of dental pain. Expert Opinion on Pharmacotherapy,2020. The pharmacological management of dental pain: Expert Opinion on Pharmacotherapy: Vol 21, No 5 (tandfonline.com)

24. Solete, P., Sindhu Ramesh & department of Conservative Dentistry and Endodontics, Saveetha Dental College, Saveetha University, Saveetha Institute of Medical and Technical Sciences, Chennai 600077, India. (2021). Comparative evaluation of various analgesics in irreversible pulpitis to reduce pain. Bioinformation,2021;17(2):313–319. https://doi.org/10.6026/97320630017313

25. A Shirvani 1, S Shamszadeh 2, M J Eghbal 2, S Asgary. The efficacy of non‐narcotic analgesics on post‐operative endodontic pain: A systematic review and meta‐analysis: The efficacy of non-steroidal anti-inflammatory drugs and/or paracetamol on post-operative endodontic pain. Journal of Oral Rehabilitation,2017;44(9):709–721. https://doi.org/10.1111/joor.12519

Powered by WPeMatico

Japan accepts GSK Arexvy regulatory application to prevent RSV disease in adults aged 50-59 at increased risk

London: GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a regulatory application to extend the indication of GSK’s respiratory syncytial virus (RSV) vaccine (recombinant adjuvanted) for the prevention of RSV disease in adults aged 50-59 at increased risk.

This regulatory submission follows Japan’s approval of GSK’s vaccine for the prevention of RSV disease in adults from the age of 60 years, and the recent announcement of the positive results of a phase III trial [NCT05590403] evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV lower respiratory tract disease (LRTD) due to certain underlying medical conditions.

The burden of RSV disease in adults is likely to be underestimated due to lack of awareness and standardised testing, as well as under-detection within surveillance studies, but people with underlying medical conditions – such as chronic obstructive pulmonary disease (COPD), asthma, chronic heart failure and diabetes– are at increased risk for RSV disease. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation, or death. An international systematic review of the prevalence of respiratory viruses in patients with acute exacerbations of COPD, for example, showed that RSV was detected 1 in 10 cases.

Further announcements on regulatory progress in the US and EU are expected in early 2024.

Read also: GSK RSV shot Arexvy approved in Britain for adults aged 60 years and older

Powered by WPeMatico

Gene polymorphisms linked to development of recurrent urolithiasis

Researchers have found in a new study that Gene polymorphisms is linked to development of recurrent urolithiasis. 

The findings of the study have been published in the Journal BMC Nephrology. 

Urolithiasis is one of the most prevalent diseases worldwide. Its prevalence is rising, both in developing and developed countries. Currently, the incidence and prevalence of urolithiasis is on the rise worldwide. Approximately 12% population of the world was affected by urolithiasis regardless of age, race, or sex.

It is known that genetic factors play big roles in the development of urolithiasis. One of the suspected factors is gene polymorphism. This study aims to find an accurate estimate of the association between genetic polymorphism and the risk of recurrent urolithiasis.

A systematic review and meta-analysis were performed on 12 studies from 3 databases that investigated gene polymorphism as an risk factor of urolithiasis. The review was done using Review Manager® version 5.3.The study was conducted through a comprehensive search from Medline/PubMed, Scopus, and Cochrane electronic databases for studies published between January 2000 and June 2023.

Results

Insignificant heterogenicity was found in this study. Populations from Asia and the Middle East are more likely to experience recurrent urolithiasis. Additionally, variation in the VDR and urokinase genes, particularly in the Asian population, increases the risk of developing recurrent urolithiasis.

The researchers found that Gene polymorphisms have significant roles in the development of urolithiasis, especially in the Middle Eastern region.Additionally, both VDR and urokinase gene polymorphism contributes to the susceptibility of recurrent urolithiasis particularly for the Asian population in the latter. Studies with a variety of population characteristics are recommended to be performed to further support our results.

Reference:

Rasyid, N., Soedarman, S. Genes polymorphism as risk factor of recurrent urolithiasis: a systematic review and meta-analysis. BMC Nephrol 24, 363 (2023). https://doi.org/10.1186/s12882-023-03368-y

Keywords:

Gene, polymorphisms, linked, development, urolithiasis, BMC Nephrology, Rasyid, N., Soedarman, S

Powered by WPeMatico

Middle ear pressure therapy using special device effectively controls vertigo symptoms

A recent study has shed light on the promising long-term benefits of Middle Ear Pressure Therapy (MEPT) utilizing the EFET01 device in patients diagnosed with Ménière’s disease (MD) and delayed endolymphatic hydrops (DEH) in Japan. The investigation aimed to evaluate the effects of MEPT over two years in reducing vertigo attacks and improving hearing in individuals with MD and DEH. This study was published in Acta Oto-Laryngologica journal by Do Tram Anh and colleagues.

Conducted retrospectively from December 2018 to April 2021, the study included 32 MD patients and 2 DEH patients who underwent MEPT with the EFET01 device. Patients were assessed based on the Japan Society for Equilibrium Research (JSER) guidelines, tracking the frequency of vertigo attacks and changes in hearing levels for 6 months before treatment initiation up to 18–24 months post-treatment.

The results revealed significant reductions in the frequency of vertigo attacks in both MD and DEH patients following MEPT. Furthermore, the study noted a sustained stability in hearing levels for the majority of patients post-treatment.

The findings underscore the efficacy of MEPT utilizing the EFET01 device in effectively managing vertigo symptoms associated with MD and DEH. The therapy showcased its potential as a safe and beneficial option, especially for patients who had not responded well to conventional medical treatments.

These promising outcomes pave the way for MEPT to be considered as a valuable alternative in the management of MD and DEH, offering hope for individuals who have experienced limited success with traditional therapies. The sustained reduction in vertigo attacks and stability in hearing levels post-treatment emphasize the potential of MEPT to significantly impact the quality of life for these patients over an extended period.

Reference:

Tram Anh, D., Takakura, H., Nakazato, A., Morita, Y., & Shojaku, H. Long-term effects of middle ear pressure therapy with the EFET01 device in patients with Ménière’s disease and delayed endolymphatic hydrops in Japan. Acta Oto-Laryngologica,2023;1–5. https://doi.org/10.1080/00016489.2023.2284336

Powered by WPeMatico